November 9, 2015
AstraZeneca K.K.’s AZD9291, an investigational treatment for EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), gained priority regulatory review status in Japan, the company said on November 6. The agent had been filed for Japan approval in August for the...read more